Anti-infective Agents Market
Report ID: SQMIG35I2778
Report ID: SQMIG35I2778
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2778 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
93
|Figures:
76
Global Anti-Infective Agents Market size was valued at USD 135.43 Billion in 2024 and is poised to grow from USD 137.61 Billion in 2025 to USD 156.37 Billion by 2033, growing at a CAGR of 1.61% during the forecast period (2026-2033).
The primary driver of the anti-infective market is the global burden of infectious diseases, which compels ongoing innovation and distribution of antibiotics, antivirals, antifungals and antiparasitics. Anti infectives include prescription medicines, over the counter remedies and biologics used to prevent and treat infections in human medicine, and they matter because resistance, pandemic shocks and aging societies intensify demand for effective care. Over decades the sector moved from broad spectrum synthetic antibiotics toward targeted small molecules and monoclonal antibodies, illustrated by the transition from penicillin dominance in mid twentieth century to modern antiviral regimens and stewardship programs that shape utilization.
Building on evolving utilization patterns, a key trend driving the global anti-infective agents sector growth is rising antimicrobial resistance worldwide, which forces investment in novel therapeutics and rapid diagnostics because ineffective legacy drugs raise morbidity, prolong hospital stays and increase costs. Consequently firms and governments fund targeted small molecules, monoclonal antibodies and point of care tests, evidenced by accelerated antiviral programs in the COVID 19 crisis and renewed attention to antifungals for invasive candidemia. Regulatory incentives and public private partnerships convert urgency into opportunity by derisking R&D, while expanding access in emerging economies and integrated diagnostics with stewardship programs sustain long term market expansion.
How is AI Accelerating Drug Discovery in the Anti-infective Agents Market?
AI has increased the speed of anti-infective drug development by improving target identification, molecule design and the prioritisation of experiments. Machine learning-based models bring together both biological and chemical datasets to identify conserved mechanisms within both bacterial and viral pathogens and allow researchers to concentrate their efforts on breadth-of-spectrum targets. Generative models propose novel peptides and small molecules while virtual screening and predictive safety models help triage leads. This shifts the market from long trial and error toward faster design build test learn cycles. As a result the anti-infective landscape is becoming more pipeline rich and attractive to investors and public health programs.
In March 2026, Decoy Therapeutics announced a strategic AI relationship with Quantori and Google Cloud that increased computational peptide design capacity and accelerated candidate discovery. This concrete example shows how AI scales design throughput shortens iteration cycles and supports more efficient pipeline generation in the anti-infective market.
Market snapshot - (2026-2033)
Global Market Size
USD 135.43 Billion
Largest Segment
Antibacterial Agents
Fastest Growth
Antiviral Agents
Growth Rate
1.61% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global anti-infective agents market is segmented by type, route of administration, end-user and region. Based on type, the market is segmented into antibacterial agents, antiviral agents, antifungal agents and others. Based on route of administration, the market is segmented into oral, parenteral, topical and others. Based on end-user, the market is segmented into hospitals, homecare settings, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per the global anti-infective agents market growth, oral segment dominates because widespread preference for pill and capsule formulations drives primary care prescribing and outpatient therapy adoption in the Anti-infective Agents Market. Ease of administration and improved patient adherence lead clinicians and payers to favor oral options for many bacterial and viral indications, prompting manufacturers to prioritize oral formulation development and commercialization. Lower cost and decreased logistical complexity give additional support for widespread accessibility throughout different types with an ongoing demand for the product, thus continuing to warrant an ongoing investment into the line of products.
However, parenteral is emerging as the most rapidly expanding area due to growing demand for injectable therapies in severe and hospital-managed infections and the rise of long acting injectable antivirals and antifungals. Advances in formulation and delivery technologies, along with regulatory support for complex injectables, are accelerating adoption and opening new treatment settings and commercial opportunities.
Hospitals segment dominates because inpatient settings manage the most complex infectious cases and drive demand for high acuity anti-infective therapies in the Anti-infective Agents Market. The path towards a successful hospital formulary is primarily determined by clinical stewardship teams working in conjunction with hospital medications, which will lead to more money being spent on parenteral and advanced agents. Manufacturers are compelled to develop and maintain their products for hospitals and their supply chains because of their commitment to develop new therapeutics and diagnostic technologies and the use of consolidated purchasing and participation in clinical research.
Meanwhile, homecare settings are emerging as the fastest growing care area as shifts toward outpatient infusion, oral first strategies and remote monitoring enable more anti-infective treatments outside institutional walls. Innovations in portable infusion devices, simplified regimens and payer support for home-based care expand access, lower institutional costs, and create new commercial pathways for manufacturers focusing on decentralized delivery.
To get detailed segments analysis, Request a Free Sample Report
As per the global anti-infective agents market share, North America dominates the industry due to a convergence of advanced research capabilities, a dense concentration of leading pharmaceutical and biotech companies, and a mature healthcare ecosystem that supports rapid adoption of novel therapies. Accelerated development and commercialization of drugs are enhanced by vigorous clinical trial networks along with collaborative systems between the pharmaceutical industry and academic institutions. Predictable regulatory pathways (despite the many regulatory hurdles involved) provide the investor community with encouragement for investing in new product development due to being able to predict when products will actually reach the market. In addition, in order for target therapies to be utilized, there must be a sufficient level of quality laboratory infrastructure in addition to adequate capacity for production and sufficient availability of proficient workers. The organizations continue to maintain their leadership position with respect to drug development as well as market share.
Anti-infective agents market in United States benefits from deep research ecosystems, leading pharmaceutical and biotech presence, and extensive clinical trial infrastructure that accelerate product development and market entry. Advanced diagnostics and integrated hospital systems support targeted therapy uptake, while established manufacturing and distribution networks ensure supply continuity. Access to favourable funding sources and collaborations between universities and companies create a diversified product pipeline and commercialisation strategies that will establish this market as a centre of innovation and translation.
Anti-infective agents market in Canada is supported by a stable healthcare framework, strong public payer engagement, and collaborative research networks that foster clinical development and adoption. There is a focus on appropriate use and providing specific therapy in order to develop stewardship in the area of antimicrobials and improve diagnostic capabilities. The use of innovation centers and coordinating regulatory interaction allow the two entities to work together more easily. Increasing activity in biotechnology, availability of highly-trained professionals, and the stability of manufacturing and distribution support the commercialization and growth of companies.
Based on global anti-infective agents regional forecast, Europe the anti-infective agents market is expanding rapidly driven by a combination of strong public health priorities, active industry investment, and coordinated regulatory and reimbursement mechanisms that facilitate market access. National research centers and established pharmaceutical players invest in both next generation antimicrobials and diagnostics, while cross border collaborations support clinical trial recruitment and knowledge sharing. The growing concern about resistant organisms has increased policy focus and funding of stewardship and targeted therapy programs. In addition, due to adoption of advanced diagnostics, precision of prescribing will improve and new agents will become available more rapidly. Although the fragmented nature of the national systems will require customized market strategies, the overall integration of innovation, payer engagement, and scientific experience across the major markets will continue to provide momentum and improve regional competitiveness in their development and commercialization.
Anti-infective agents market in Germany reflects a strong industrial base with established pharmaceutical and manufacturing capabilities that support both large scale production and innovation. practical regulatory environment where reimbursement for new therapies has a clear path to the marketplace allows for predictable methods to enter that market. Coordinated public health initiatives that demonstrate the value of stewardship create the framework in which to develop or commercialize products successfully through strategic partnerships between those research institutions and companies in the medical field.
Anti-infective agents market in United Kingdom is driven by a dynamic innovation ecosystem, active funding for biotech, and strong translational research that links academic discovery to commercial development. National health service engagement and pragmatic regulatory approaches support pilot adoption and evaluation. Emphasis on rapid diagnostics and novel therapeutic approaches, combined with cross sector partnerships, encourages accelerated commercialization and positions United Kingdom as an active market for next generation anti-infective solutions.
Anti-infective agents market in France is emerging through targeted public private initiatives, growing biotech activity and strengthened clinical research capacity that supports pipeline advancement. Key national health priorities include an emphasis on stewardship of resources, improving the quality of the diagnosis process, encouraging optimal usage and adoption of appropriate treatment options through targeted therapies. Ongoing dialogue around reimbursement structures along with partnerships across sectors will provide an ecosystem for successful commercialisation and localised expansion into new markets.
As per global anti-infective agents regional outlook, Asia Pacific is strengthening its position in the anti-infective agents market through a mix of enhanced research investment, expanding manufacturing capacity, and progressive regulatory reforms that support commercialization. Local biotech and pharmaceutical companies have been working together with larger worldwide pharmaceutical companies more often for a better chance of developing products and increasing the supply of those products than they had done previously. There has also been a push towards producing more evidence-based medicine because of enhancements in clinical trial infrastructure. An example of a way governments have supported these improvements and evidence-based treatment is they have made the development of antimicrobial resistance (AMR) and new diagnostics an objective (and funding priority) of their governments. One method that is being used is the implementation of stewardship programs and the promotion of knowledge-based therapy regarding new drugs.
Anti-infective agents market in Japan is characterized by advanced scientific capabilities, strong domestic pharmaceutical and biotech activity, and high quality manufacturing standards that support both innovation and reliable supply. Clinical development and regulatory submissions are enabled through collaborative relationships between industry and academia and via progressive regulatory measures. Targeted therapy use will be further fostered through widespread adoption of diagnostic technologies and use of integrated care networks. In addition, developing strategic alliances with global partners will allow for increased commercial expansion into regional markets or globally.
Anti-infective agents market in South Korea is advancing through a vibrant biotech sector, focused R&D investment and high standards in biologics and manufacturing that support domestic needs and exports. Efficient pathways and approval processes between regulatory authorities enable rapid clinical assessment, as well as developing access to the marketplace. The collaborative efforts among government agencies, industry and academia allow for the advancement of research to develop commercially viable anti-infective products at an accelerated rate.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Antimicrobial Resistance
Advances In Diagnostic Technologies
High Research And Development Costs
Stringent Regulatory Requirements
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in the global anti-infective agents market outlook is defined by consolidation through targeted M&A, intensified competition for novel mechanisms driven by rising antimicrobial resistance, and active public-private funding that accelerates deal activity; examples include Shionogi’s acquisition of Qpex and the rise of generative AI discovery platforms that attract programmatic support for antibiotic R&D.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global anti-infective agents industry is anchored by strong clinical need and sustained investment. One key driver is rising antimicrobial resistance which fuels demand for novel therapeutics and diagnostics, and a second driver is advances in diagnostic technologies that enable targeted therapy and stewardship. One restraint is high research and development costs that slow new entrants and limit pipeline breadth. North America is the leading region for this industry because of its well-established research ecosystems and quick adoption rates. Also, the leading segment within this industry is oral delivery because of how much patients prefer to receive their medications this way and the trends in outpatient care. Overall, opportunities concentrate on precision therapies, AI-enabled discovery and public private partnerships.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 135.43 Billion |
| Market size value in 2033 | USD 156.37 Billion |
| Growth Rate | 1.61% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Anti-infective Agents Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Anti-infective Agents Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Anti-infective Agents Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Anti-infective Agents Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Anti-Infective Agents Market size was valued at USD 135.43 Billion in 2024 and is poised to grow from USD 137.61 Billion in 2025 to USD 156.37 Billion by 2033, growing at a CAGR of 1.61% during the forecast period (2026-2033).
Competitive landscape in the global anti-infective agents market is defined by consolidation through targeted M&A, intensified competition for novel mechanisms driven by rising antimicrobial resistance, and active public-private funding that accelerates deal activity; examples include Shionogi’s acquisition of Qpex and the rise of generative AI discovery platforms that attract programmatic support for antibiotic R&D. 'Pfizer', 'Gilead Sciences', 'GlaxoSmithKline', 'Merck & Co', 'Johnson & Johnson', 'Novartis', 'Roche Holding', 'Sanofi', 'AstraZeneca', 'Bayer', 'AbbVie', 'Bristol-Myers Squibb', 'Eli Lilly and Company', 'Takeda Pharmaceutical', 'Abbott Laboratories', 'Astellas Pharma', 'Sun Pharmaceutical Industries', 'Cipla', 'Dr. Reddy's Laboratories', 'Lupin'
Rising antimicrobial resistance has increased demand for new and improved anti-infective agents, prompting pharmaceutical companies and research institutions to prioritize development of novel therapies and formulations. This pressure stimulates investment in discovery, clinical development, and expansion of product pipelines, while encouraging collaborations and licensing to accelerate time to market. The resulting focus on innovation broadens the therapeutic options available, drives commercial activity across multiple segments, and strengthens market expansion by creating opportunities for differentiated products that address persistent treatment challenges.
Precision Therapy Integration: Advances in molecular profiling and pathogen specific biomarkers enable tailored anti infective regimens, shifting development toward narrow spectrum agents and host targeted therapies. Pharmaceutical innovation focuses on companion diagnostics and trial designs to match treatments to patient pathogen profiles. Personalized dosing strategies and pharmacogenomic considerations improve therapeutic windows and safety profiles, making therapies more effective while mitigating microbiome disruption. This trend drives collaboration across diagnostics, biotech, and providers to accelerate adoption and demonstrate clinical value in targeted infectious disease management.
Why does North America Dominate the Global Anti-infective Agents Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
